| News

Polyphor receives up to 18 million dollars for development of antibiotics

15.10.2020

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor will be provided with initial funding of up to 2.62 million US dollars for its innovative antibiotics program. A maximum of 15.82 million dollars has been earmarked for later milestones.

As the life sciences company Polyphor wrote in a press release, this funding is the second major support by the global public-private consortium CARB-X and follows a previous grant in 2019. This partnership led by Boston University is dedicated to supporting the development of antibacterial products, to diagnose, prevent and treat drug-resistant infections. Polyphor is located in Allschwil in the canton of Basel-Landschaft. The Basel area is known as a leading center for antibiotic research.

This award will support the development of the novel class of antibiotics discovered by Polyphor and the University of Zurich. These show potent and specific antimicrobial activity against Enterobacteriaceae, including extremely drug resistant strains. They are among the priority-1 pathogens, as classified by the World Health Organization.

CARB-X will provide Polyphor with initial funding of up to 2.62 million US Dollars to complete the hit-to-lead stage. Up to 15.82 million dollars will additionally be granted if certain project milestones are met.

“CARB-X fosters the best science and most promising early development R&D-projects in the world,” explains Polyphor CEO Gökhan Batur in the press release. “This second award is a strong validation of our innovative antibiotic platform and an important milestone in the implementation of our renewed strategy in this field presented earlier this year.”

“Serious infections are a global health threat, due in part to the emergence of drug-resistant bacteria for which we do not have therapies,” said Erin Duffy, R&D Chief of CARB-X. “Polyphor’s project enriches the pool of novel approaches to deliver a therapeutic that can treat infections caused by multidrug-resistant Gram-negative pathogens for which we have few options. It is in the early stages of development, and if successful and approved, it could potentially change the way these life-threatening infections are treated and save lives.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area has ever more to offer investors
Basel Area Business & Innovation, Innovation, Invest

Basel Area has ever more to offer investors

The canton of Basel-Stadt has displayed the most striking performance in the Swiss Venture Capital Report. Last year, more than...

Read More
Basel researchers developing universal cancer therapy
Basel Area Business & Innovation, Innovation, Invest

Basel researchers developing universal cancer therapy

Researchers from Basel are working on the development of a therapy in which pre-prepared immune cells can be used to...

Read More
Opterion Health AG moving to Muttenz
Basel Area Business & Innovation, Innovation, Invest

Opterion Health AG moving to Muttenz

Opterion is moving from the canton of Obwalden to Muttenz in the canton of Basel-Landschaft in order to benefit from...

Read More
Evolva brings natural sugar blocker to market
Basel Area Business & Innovation, Innovation, Invest

Evolva brings natural sugar blocker to market

The biotech company Evolva is introducing L-arabinose to the market. This product is a natural sugar blocker and can be...

Read More
Holmusk opens new office in Basel
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Holmusk opens new office in Basel

Holmusk has opened an office in Basel. The company from Singapore develops digital therapies on the basis of data analysis....

Read More
Zifo RnD Solutions coming to Basel
Basel Area Business & Innovation, Innovation, Invest

Zifo RnD Solutions coming to Basel

Zifo RnD Solutions, a global provider of IT solutions for research-based organizations, opens its latest subsidiary in Basel. With Zifo...

Read More
1 2 3 39

Do you have a question? We'd like to hear from you.